Evaluation of oxidative stress and effectiveness of low-dose glucocorticoid therapy on exacerbation of chronic obstructive pulmonary disease

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 62, Issue 4, 2007, Pages 459-464

  Komatsu, Fumio ^a   Kudoh, Hideki ^a   Kagawa, Yasuo ^a  

^a KAGAWA NUTRITION UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; HYDROCORTISONE; PREDNISOLONE; REACTIVE OXYGEN METABOLITE; ANTIOXIDANT; GLUCOCORTICOID;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; VITAL CAPACITY; BLOOD; DOSE RESPONSE; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34250349603     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/62.4.459     Document Type: Article

References (32)

1. Baranes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269-280.
2. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest. 2004;114:1248-1259.
3. Donma O, Donma MM. Relationship of senescence of pulmonary system to chronic obstructive pulmonary disease in the advanced life. Med Hypotheses. 2002;59:208-211.
4. Snow V, Lasher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001;134:595-599.
5. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001;134:600-620.
6. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941-1947.
7. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JAE. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(1):CD001288.
8. Cornelli U, Cornelli M, Terranova R. Free-radical and vascular disease. Int Union Angiol Bull. 1999;15:7-10.
9. Repine JE, Bast A, Lankhorst I. The Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:341-357.
10. Cesarone MR, Belcaro G, Carratelli M, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127-130.
11. Trotti R, Carratelli M, Barbieri M, et al. Oxidative stress and a thrombophilic condition in alcoholics without severe liver disease. Haematologica. 2001;86:85-91.
12. Dani C, Martelli E, Bertini G, et al. Plasma bilirubin level and oxidative stress in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2003;88:119-123.
13. Carratelli M, Porcaro L, Ruscica M, De Simone E, Bertelli AAE, Corsi MM. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res. 2001;21:79-84.
14. Yagi K, Ohkawa H, Ohishi N, Yamashita M, Nakashima T. Lesion of aortic intima caused by intravenous administration of linoleic acid hydroperoxide. J Appl Biochem. 1981;3:58-65.
15. Gerardi G, Usberti M, Martini G, et al. Plasma total antioxidant capacity in hemodialyzed patients and its relationships to other biomarkers of oxidative stress and lipid peroxidation. Clin Chem Lab Med. 2002;40:104-110.
16. Ippolito S, Caruso R, Novembrino C, et al. Dislipidemia and oxidative stress. Ital J Biochem. 2002;51:129.
17. Global Initiative for Chronic Obstructive Lung Disease. National Heart, Lung, and Blood Institute, National Institutes of Health; April 2001. Publication 2701.
18. Yagi K, Komura S, Kayahara N, Tatano T, Ohishi N. A simple assay for lipid hydroperoxides in serum or plasma. J Clin Biochem Nutr. 1996;20:181-193.
19. Kitano S, Kanno T, Maekawa M, et al. Improved method for the immunological detection of malondialdehyde-modified low-density lipoproteins in human serum. Anal Chim Acta. 2004;509:229-235.
20. Shimoi K, Kasai H, Yokota N, Toyokuni S, Kinae N. Comparison between high-performance liquid chromatography and enzyme-linked immunosorbent assay for the determination of 8-hydroxy-2′-deoxyguanosine in human urine. Cancer Epidemiol Biomarkers Prev. 2002;11:767-770.
21. Oyanagi Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal Biochem. 1984;142:290-296.
22. Anzalone GE, Danesi P, Goti P, Melocchi F. Effect of aerosolized N-acetylcysteine (NAC) on reactive oxygen metabolites (ROM) in plasma of COPD patients. Le Malattie Dell'Apparato Respiratorio. 2001;4:41-45.
23. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004;23:629-636.
24. Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21:795-798.
25. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005;365:1552-1560.
26. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440:944-948.
27. Hagihara M, Nishigaki I, Maseki M, Yagi K. Age-dependent changes in lipid peroxide levels in the lipoprotein fractions of human serum. J Gerontol. 1984;39:269-272.
28. Kim YT, Kim JW, Choi JS, Kim SH, Choi EK, Cho NH. Relation between deranged antioxidant system and cervical neoplasia. Int J Gynecol Cancer. 2004;14:889-895.
29. Tsuboi H, Kouda K, Takeuchi H, et al. 8-Hydroxydeoxyguanosine in urine as an index of oxidative damage to DNA in the evaluation of atopic dermatitis. Br J Dermatol. 1998;138:1033-1035.
30. Dekhuijzen PNR, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:813-816.
31. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Bames PJ. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1635-1639.
32. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59-65.